Evotec (EVO) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed Evotec (EVO) over the past year, losing 44.2% versus a loss of 55.6%. Over five years, GYRE leads with a -77.5% price change compared with -94.4% for EVO. Evotec is the larger company by market cap ($469.1 million vs $460.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | GYRE |
|---|---|---|
| Share price | $1.32 | $4.21 |
| Market cap | $469.11M | $460.79M |
| 1-day change | -8.97% | -6.86% |
| YTD return | -57.14% | -40.37% |
| 1-year return | -55.56% | -44.24% |
| 5-year return | -94.44% | -77.55% |
| Forward P/E | — | 70.17 |
| EPS (TTM) | $-0.59 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $116.59M |
| Revenue growth (YoY) | — | +10.24% |
| Net income (latest FY) | — | $9.88M |
| Gross margin | — | 95.35% |
| Operating margin | — | 9.85% |
| Net margin | — | 8.47% |
| 52-week high | $3.87 | $9.14 |
| 52-week low | $1.32 | $3.97 |
| Distance from 52-week high | -65.89% | -53.94% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +237.12% | +343.47% |
| Average volume | 109.16K | 181.04K |
| Shares outstanding | 355.39M | 109.45M |
| Employees | 4,379 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GYRE has outperformed EVO by 11.3 percentage points over the past year.
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
EVO vs GYRE FAQ
Which is bigger, Evotec or Gyre Therapeutics?
Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $460.79M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, EVO or GYRE?
GYRE returned -44.24% over the past 12 months, compared with -55.56% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Evotec and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.